The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury.

[1]  J. Wagner,et al.  CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation. , 2007, The Journal of investigative dermatology.

[2]  Y. Helfrich,et al.  Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. , 2007, The Journal of clinical investigation.

[3]  P. Elias,et al.  Transepidermal water loss reflects permeability barrier status: validation in human and rodent in vivo and ex vivo models , 2006, Experimental dermatology.

[4]  T. Hökfelt,et al.  The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection , 2006, Nature Medicine.

[5]  D. Atanackovic,et al.  Physiology and Pharmacology of Temperature Regulation Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive / memory T-cell subtypes , 2006 .

[6]  V. Nizet,et al.  The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  F. Dhabhar,et al.  Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity. , 2005, International immunology.

[8]  D. O'Connor,et al.  Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. , 2005, The Journal of clinical investigation.

[9]  M. Kagnoff,et al.  Cathelicidin Mediates Innate Intestinal Defense against Colonization with Epithelial Adherent Bacterial Pathogens1 , 2005, The Journal of Immunology.

[10]  C. Haglund,et al.  Neuroendocrine differentiation in primary Merkel cell carcinoma--possible prognostic significance. , 2005, Anticancer research.

[11]  A. Di Nardo,et al.  Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. , 2005, The Journal of investigative dermatology.

[12]  K. Helle,et al.  New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A , 2005, Cellular and Molecular Life Sciences CMLS.

[13]  N. McCallum,et al.  Reduced Content of Lysyl-Phosphatidylglycerol in the Cytoplasmic Membrane Affects Susceptibility to Moenomycin, as Well as Vancomycin, Gentamicin, and Antimicrobial Peptides, in Staphylococcus aureus , 2004, Antimicrobial Agents and Chemotherapy.

[14]  D. O'Connor,et al.  The Catecholamine Release-Inhibitory “Catestatin” Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses , 2004, Molecular Pharmacology.

[15]  D. O'Connor,et al.  Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A , 2004, Regulatory Peptides.

[16]  V. Nizet,et al.  Antimicrobial peptides and the skin , 2004, Expert opinion on biological therapy.

[17]  A. Villa,et al.  Chromogranin A protects vessels against tumor necrosis factor α‐induced vascular leakage , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  R. Gallo,et al.  Postsecretory Processing Generates Multiple Cathelicidins for Enhanced Topical Antimicrobial Defense1 , 2004, The Journal of Immunology.

[19]  Douglas W. Smith,et al.  Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. , 2004, American journal of human genetics.

[20]  K. Kurokawa,et al.  Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. , 2004, Microbiology.

[21]  D. Aunis,et al.  Innate immunity: involvement of new neuropeptides. , 2003, Trends in microbiology.

[22]  P. Bradford,et al.  Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. , 2003, Biochimica et biophysica acta.

[23]  D. Aunis,et al.  Antimicrobial Chromogranins and Proenkephalin‐A—Derived Peptides , 2003 .

[24]  J. C. Tony.  The chromogranin-secretogranin family. , 2003, The New England journal of medicine.

[25]  D. Aunis,et al.  Antimicrobial chromogranins and proenkephalin-A-derived peptides: Antibacterial and antifungal activities of chromogranins and proenkephalin-A-derived peptides. , 2003, Annals of the New York Academy of Sciences.

[26]  Tomas Ganz,et al.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis. , 2002, The New England journal of medicine.

[27]  D. O'Connor,et al.  Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. , 2002, Journal of hypertension.

[28]  Robert E W Hancock,et al.  Cationic peptides: distribution and mechanisms of resistance. , 2002, Current pharmaceutical design.

[29]  Takaaki Ohtake,et al.  Innate antimicrobial peptide protects the skin from invasive bacterial infection , 2001, Nature.

[30]  D. O'Connor,et al.  Proteolytic Cleavage of Chromogranin A (CgA) by Plasmin , 2001, The Journal of Biological Chemistry.

[31]  V. Nizet,et al.  Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. , 2001, The Journal of investigative dermatology.

[32]  Michael Otto,et al.  Staphylococcus aureus Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor Mprf Is Based on Modification of Membrane Lipids with l-Lysine , 2001, The Journal of experimental medicine.

[33]  J. Schröder,et al.  Isolation and Characterization of Human β-Defensin-3, a Novel Human Inducible Peptide Antibiotic* , 2001, The Journal of Biological Chemistry.

[34]  D. Aunis,et al.  Antibacterial and Antifungal Activities of Vasostatin-1, the N-terminal Fragment of Chromogranin A* , 2000, The Journal of Biological Chemistry.

[35]  J. M. Lipton,et al.  Antimicrobial effects of α‐MSH peptides , 2000 .

[36]  J. M. Lipton,et al.  Antimicrobial effects of alpha-MSH peptides. , 2000, Journal of Leukocyte Biology.

[37]  D. Torpy,et al.  Stress, Corticotropin‐Releasing Hormone, Glucocorticoids, and the Immune/Inflammatory Response: Acute and Chronic Effects a , 1999, Annals of the New York Academy of Sciences.

[38]  S. Yoshikawa,et al.  Enhancement of Antimicrobial Activity of Neuropeptide Y by N-Terminal Truncation , 1998, Antimicrobial Agents and Chemotherapy.

[39]  R. Bals,et al.  The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. O'Connor,et al.  Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo , 1998, Peptides.

[41]  D. Low,et al.  Reduced Virulence of Group A Streptococcal Tn916 Mutants That Do Not Produce Streptolysin S , 1998, Infection and Immunity.

[42]  D. O'Connor,et al.  A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis. , 1998, Advances in pharmacology.

[43]  R. Siebert,et al.  Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. , 1997, Genomics.

[44]  D. O'Connor,et al.  Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. , 1997, The Journal of clinical investigation.

[45]  M. Ackermann,et al.  Epithelial antibiotic induced in states of disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. Trinchieri,et al.  Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. , 1997, The Journal of investigative dermatology.

[47]  G. Trinchieri,et al.  Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. , 1997, Journal of Investigative Dermatology.

[48]  D. O'Connor,et al.  Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. , 1996, The Journal of clinical investigation.

[49]  A. Laslop,et al.  Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin , 1995, Progress in Neurobiology.

[50]  M. Claeys,et al.  Posttranslational processing of proenkephalins and chromogranins/secretogranins , 1993, Neurochemistry International.

[51]  P. Elias,et al.  Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. , 1992, The Journal of clinical investigation.

[52]  D. O'Connor,et al.  Chromogranin A. Storage and release in hypertension. , 1990, Hypertension.

[53]  D. O'Connor,et al.  Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. , 1988, The American journal of surgical pathology.

[54]  W. Huttner,et al.  Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. , 1983, The Journal of biological chemistry.

[55]  D. O'Connor.  Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum , 1983, Regulatory Peptides.

[56]  K. Helle,et al.  The release of protein from the stimulated adrenal medulla. , 1965, The Biochemical journal.